학술논문

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Document Type
Article
Source
Frontiers in Neurology; 3/22/2023, Vol. 14, p1-9, 9p
Subject
ERENUMAB
CALCITONIN gene-related peptide
MIGRAINE
MONOCLONAL antibodies
COHORT analysis
Language
ISSN
16642295
Abstract
Copyright of Frontiers in Neurology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)